Expanded Access to Telisotuzumab Vedotin
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04830202 |
Expanded Access Status :
Available
First Posted : April 5, 2021
Last Update Posted : April 3, 2024
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Non-Small Cell Lung Cancer (NSCLC) | Drug: Telisotuzumab vedotin |
Study Type : | Expanded Access |
Expanded Access Type : | Individual Patients |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | Expanded Access to Telisotuzumab Vedotin |
- Drug: Telisotuzumab vedotin
Intravenous InfusionOther Name: ABBV-399
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The participant must not be eligible for a telisotuzumab vedotin clinical trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04830202
Contact: ABBVIE CALL CENTER | 844-663-3742 | abbvieclinicaltrials@abbvie.com |
United States, California | |
Sutter Medical Group /ID# 254816 | Available |
Sacramento, California, United States, 95816 | |
United States, New Jersey | |
Oncology & Hematology Specialist /ID# 248083 | Available |
Mountain Lakes, New Jersey, United States, 07046-1743 | |
Australia, Western Australia | |
Western Heamatology and Oncology Clinics /ID# 243364 | Available |
West Perth, Western Australia, Australia, 6005 | |
Germany | |
University Hospital Cologne /ID# 254773 | Available |
Cologne, Germany, 50937 | |
Asklepios Fachkliniken Muenchen-Gauting /ID# 259196 | Available |
Gauting, Germany, 82131 | |
Hong Kong | |
Hong Kong United Oncology Centre /ID# 241857 | Available |
Yau Ma Tei, Hong Kong | |
Israel | |
The Chaim Sheba Medical Center /ID# 256530 | Available |
Ramat Gan, Tel-Aviv, Israel, 5265601 | |
Shaare Zedek Medical Center /ID# 252374 | Available |
Jerusalem, Israel, 91031 | |
Rabin Medical Center /ID# 228611 | Available |
Petakh Tikva, Israel, 4941492 |
Study Director: | ABBVIE INC. | AbbVie |
Responsible Party: | AbbVie |
ClinicalTrials.gov Identifier: | NCT04830202 |
Other Study ID Numbers: |
C20-503 |
First Posted: | April 5, 2021 Key Record Dates |
Last Update Posted: | April 3, 2024 |
Last Verified: | April 2024 |
Non-Small Cell Lung Cancer (NSCLC) Telisotuzumab vedotin ABBV-399 Expanded Access Pre-approval Access |
Compassionate Use Special Access Program Named Patient Basis Special Access Scheme |
Carcinoma, Non-Small-Cell Lung Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |